Cumberland Pharmaceuticals (CPIX) Stock Rating Lowered by ValuEngine

Cumberland Pharmaceuticals (NASDAQ:CPIX) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a report issued on Monday.

Shares of Cumberland Pharmaceuticals (NASDAQ CPIX) opened at $7.25 on Monday. The company has a current ratio of 4.18, a quick ratio of 3.81 and a debt-to-equity ratio of 0.12. Cumberland Pharmaceuticals has a 12 month low of $5.16 and a 12 month high of $7.96.

Hedge funds have recently modified their holdings of the stock. Ameriprise Financial Inc. lifted its stake in Cumberland Pharmaceuticals by 0.3% during the second quarter. Ameriprise Financial Inc. now owns 23,892 shares of the specialty pharmaceutical company’s stock worth $167,000 after purchasing an additional 80 shares during the last quarter. Vanguard Group Inc. lifted its stake in Cumberland Pharmaceuticals by 0.4% during the second quarter. Vanguard Group Inc. now owns 298,635 shares of the specialty pharmaceutical company’s stock worth $2,111,000 after purchasing an additional 1,180 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Cumberland Pharmaceuticals by 0.3% during the second quarter. Dimensional Fund Advisors LP now owns 866,283 shares of the specialty pharmaceutical company’s stock worth $6,125,000 after purchasing an additional 2,464 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Cumberland Pharmaceuticals by 5.2% during the first quarter. Renaissance Technologies LLC now owns 270,240 shares of the specialty pharmaceutical company’s stock worth $1,875,000 after purchasing an additional 13,240 shares during the last quarter. Finally, Essex Investment Management Co. LLC lifted its stake in Cumberland Pharmaceuticals by 116.1% during the third quarter. Essex Investment Management Co. LLC now owns 34,494 shares of the specialty pharmaceutical company’s stock worth $244,000 after purchasing an additional 18,535 shares during the last quarter. Institutional investors and hedge funds own 34.44% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://ledgergazette.com/2017/12/06/cumberland-pharmaceuticals-cpix-stock-rating-lowered-by-valuengine.html.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company’s product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H.

Receive News & Ratings for Cumberland Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply